Reduced Intensity Conditioning Regimens for Acute Myeloid Leukemia and Myelodysplastic Syndrome
Acute Myeloid Leukemia, Adult, Myelodysplastic Syndrome(MDS), Allogeneic Hematopoietic Stem Cell Transplantation
About this trial
This is an interventional treatment trial for Acute Myeloid Leukemia, Adult focused on measuring hematopoietic stem cell transplantation (HSCT), reduced intensity conditioning (RIC), Acute Myeloid Leukemia(AML), Myelodysplastic Syndrome(MDS)
Eligibility Criteria
Inclusion Criteria: Age equal or more than 18 years old. Patients diagnosed with AML or MDS. Patients who have related or unrelated bone marrow or peripheral blood donors and plan to undergo hematopoietic stem cell transplantation. Hct-specific complication index score (HCT-CI) more than or equal to 3 or the age of Patients ≥55 years. Sign the informed consent, promise to abide by the research procedures, and cooperate with the implementation of the whole process of the research. Exclusion Criteria: Patients with central nervous system involvement. Patients with HIV seropositive. Patients with other serious diseases and a life expectancy of less than six months Patients with severe mental or psychological disorders. Patients without written informed consent.
Sites / Locations
- Wuhan Union Hospital, Tongji Medical college, Huazhong University of Science and TechnologyRecruiting
Arms of the Study
Arm 1
Arm 2
Active Comparator
Experimental
fludarabine and busulfan
fludarabine and melphalan
fludarabine (30 mg/m^2/day, days -6 to days -2, the total dase is 150 mg/m^2) and busulfan (3.2 mg/kg/day, days -3 to days -2, the total dose is 6.4 mg/kg)
fludarabine (30 mg/m^2/day, days -6 to days -2, the total dose is 150 mg/m^2) and melphalan (70 mg/m^2/day, days -3 to days -2, the total dose is 140 mg/m^2)